aTyr Pharma Inc reports results for the quarter ended in December - Earnings Summary

aTyr Pharma

14/03/2024 21:01

* aTyr Pharma Inc  LIFE.OQ  reported a quarterly adjusted
loss
of 25 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -26 cents.  The mean expectation of
five analysts for the quarter was for a loss of 24 cents per
share. Wall Street expected results to range from -28 cents
to -21 cents per share.
    * Reported revenue was zero​; analysts expected $52.00
thousand. 
    * aTyr Pharma Inc's reported EPS for the quarter was a loss
of 25
cents​.
    * The company reported a quarterly loss of $14.76 million.
    * aTyr Pharma Inc shares had risen by 15.6% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for aTyr Pharma Inc
is $25.00 
This summary was machine generated from LSEG data March 14 at
09:00 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.24          -0.25          Missed
 Sep. 30 2023      -0.23          -0.20          Beat
 Jun. 30 2023      -0.28          -0.22          Beat
 Mar. 31 2023      -0.40          -0.29          Beat